These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Alvarez T; Miller E; Duska L; Oliva E Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825 [TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767 [TBL] [Abstract][Full Text] [Related]
25. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Ta RM; Hecht JL; Lin DI Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772 [TBL] [Abstract][Full Text] [Related]
26. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma]. Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256 [No Abstract] [Full Text] [Related]
27. Molecular characterization in the prediction of disease extent in endometrial carcinoma. Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447 [TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243 [TBL] [Abstract][Full Text] [Related]
30. Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging. Espinosa I; D'Angelo E; Prat J Gynecol Oncol; 2024 Jul; 186():94-103. PubMed ID: 38615479 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778 [TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472 [TBL] [Abstract][Full Text] [Related]
33. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology. Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131 [TBL] [Abstract][Full Text] [Related]
34. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061 [TBL] [Abstract][Full Text] [Related]
35. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142 [TBL] [Abstract][Full Text] [Related]
37. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598 [TBL] [Abstract][Full Text] [Related]
38. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210 [TBL] [Abstract][Full Text] [Related]
39. Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components. Hammer PM; Wang A; Vermij L; Zdravkovic S; Heilbroner L; Ryan E; Geisick RLP; Charu V; Longacre TA; Suarez CJ; Ho C; Jenkins TM; Mills AM; Bosse T; Howitt BE Am J Surg Pathol; 2024 Aug; 48(8):953-964. PubMed ID: 38780000 [TBL] [Abstract][Full Text] [Related]
40. The Significance of International Federation of Gynecology and Obstetrics Grading in Microsatellite Instability-High and POLE-Mutant Endometrioid Endometrial Carcinoma. Kertowidjojo E; Momeni-Boroujeni A; Rios-Doria E; Abu-Rustum N; Soslow RA Mod Pathol; 2023 Sep; 36(9):100234. PubMed ID: 37268062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]